EQL Pharma ABOSTO:EQL -2.32%42 Market Cap is kr683.6 Mil as of Jul. 03, 2026. GuruFocus rates OSTO:EQL with a GF Score™ of 42/100. The stock has 4 warning signs investors should review. Among 1,024 Drug Manufacturers companies, EQL Pharma AB ranks worse than 64.84% on this metric.
Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). EQL Pharma AB's share price for the quarter that ended in Mar. 2026 was kr54.4. EQL Pharma AB's Shares Outstanding (EOP) for the quarter that ended in Mar. 2026 was 29.5 Mil. Therefore, EQL Pharma AB's market cap for the quarter that ended in Mar. 2026 was kr1,606.4 Mil.
EQL Pharma AB's quarterly market cap
declined
from Sep. 2025 (kr1,949.0 Mil) to Dec. 2025 (kr1,706.8 Mil) and
declined
from Dec. 2025 (kr1,706.8 Mil) to Mar. 2026 (kr1,606.4 Mil).
EQL Pharma AB's annual market cap
increased
from Mar. 2024 (kr0.0 Mil) to Mar. 2025 (kr2,063.5 Mil) but then
declined
from Mar. 2025 (kr2,063.5 Mil) to Mar. 2026 (kr1,606.4 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. EQL Pharma AB's Enterprise Value for Today is kr1,082.0 Mil.
EQL Pharma AB (OSTO:EQL) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
EQL Pharma AB Market Cap Related Terms
EQL Pharma AB Market Cap Historical Data
* Premium members only.
The historical data trend for EQL Pharma AB's Market Cap can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, EQL Pharma AB's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
EQL Pharma AB Market Cap vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, EQL Pharma AB's Market Cap distribution charts can be found below:
* The bar in red indicates where EQL Pharma AB's Market Cap falls into.
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
EQL Pharma AB's Market Cap for the fiscal year that ended in Mar. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EQL Pharma AB (OSTO:EQL) has a Market Cap of kr683.6 Mil as of Jul. 03, 2026. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on EQL Pharma AB and its competitors. According to the industry distribution chart, EQL Pharma AB ranks #664 out of 1024 companies in the Drug Manufacturers industry, placing it in the top 64.8%.
Is EQL Pharma AB's Market Cap too high?
EQL Pharma AB's current Market Cap is kr683.6 Mil. Based on the distribution chart, EQL Pharma AB ranks #664 out of 1024 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, EQL Pharma AB has a GF Score™ of 42/100, reflecting its overall financial health beyond just this single metric.
How does EQL Pharma AB's Market Cap compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, EQL Pharma AB ranks #664 out of 1024 companies for Market Cap. This places EQL Pharma AB in the lower half of its industry. The industry median Market Cap is 217.83. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Market Cap for a Drug Manufacturers company?
The median Market Cap among Drug Manufacturers companies is 217.83, based on 1,024 companies in the industry. Companies in the top quartile (top 25%) have a Market Cap significantly above this median, while those in the bottom quartile fall well below. However, Market Cap should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Market Cap mean?
A high Market Cap can signal that a stock is expensive relative to its fundamentals. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on EQL Pharma AB and its competitors. For the Drug Manufacturers industry, the median Market Cap is 217.83 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. EQL Pharma AB's current Market Cap is kr683.6 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is EQL Pharma AB stock overvalued right now?
EQL Pharma AB (OSTO:EQL) has a current Market Cap of kr683.6 Mil. The current Market Cap is kr683.6 Mil. EQL Pharma AB's overall GF Score™ is 42/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Market Cap calculated?
Market Cap is calculated from a company's financial statements. For EQL Pharma AB (OSTO:EQL), the current Market Cap is kr683.6 Mil as of Jul. 03, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
EQL Pharma AB is a pharmaceutical company focused on efficiently and thoughtfully developing and marketing generic drugs. The company operates in one segment, which is medicine. Its niche generics are divided into four parts based on four sales and marketing models: Retail, Hospital, Branded, and Tests. EQL Pharma specializes in identifying, developing, and selling generics, i.e., medicines that are medically equivalent to originator medicines. The company operates in Sweden, Denmark, Norway, Finland, the rest of Europe, and outside Europe, generating the majority of its revenue from Sweden.
42GF Score
Get the complete analysis for OSTO:EQL
Market Cap is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OSTO:EQL has been successfully added to your 
